Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
NCT ID: NCT04524169
Last Updated: 2020-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
100 participants
INTERVENTIONAL
2020-11-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women
NCT02142348
A Tiered Management System of Osteoporosis in China
NCT03916289
Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy
NCT02455154
Multicenter Cohort Study on Osteoporosis
NCT02958020
Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province
NCT06915935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thymosin Alpha 1
Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Thymosin Alpha1
Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Standard Care
Participants under the regularly treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thymosin Alpha1
Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* VAS scores greater than 5
* Normal reading and understanding ability
* Communicate normally
* Volunteer to participate
Exclusion Criteria
* Serious physical disease
* Unwilling to cooperate
60 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weifeng Yu
Role: STUDY_CHAIR
Department of Anesthesiology, Renji Hospital, School of Medicine, SJTU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diansan Su
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OP pain - Immunotherapy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.